Article
Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma.
Cellular immunology - 1 Jun 1995
Dumont F J, Staruch M J, Grammer T, Blenis J, Kastner C A, Rupprecht K M
Abstract excerpt
Rapamycin (RAP) disrupts signaling events implicated in cytokine-dependent proliferation of lymphocytes and other cells. This action is known to involve the formation of molecular complexes between the drug and intracellular binding proteins, termed FKBPs. However, the biochemical target(s) for t...
Topics
- Animals
- Carrier Proteins
- Cell Division
- Cell Fusion
- DNA-Binding Proteins
- Drug Resistance
- Flow Cytometry
- Heat-Shock Proteins
- Immunosuppressive Agents
- Lymphoma, T-Cell
- Mice
- Mutation
- Polyenes
- Protein Serine-Threonine Kinases
- RNA, Messenger
- Ribosomal Protein S6 Kinases
- Sirolimus
- Tacrolimus